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Abstract
Over the past 8 years there has been a wealth of breast cancer
gene expression studies. The majority of these studies have
focused upon characterising a tumour at presentation, before
treatment, rather than looking at the effects of treatment on the
tumour. More recently, a number of groups have moved from
predicting prognosis based upon long-term follow-up to alternative
approaches of using expression profiling to measure the effect of
treatment on breast tumours and potentially predict response to
therapy using either post-treatment samples or both pre-treatment
and post-treatment samples. Whilst this provides great potential to
further our understanding of the mode of action of treatments and
to more accurately select which patients will benefit from a
particular treatment, serious issues of experimental design must be
considered.
In the present issue of Breast Cancer Research, Vendrell and
colleges describe a candidate molecular signature associa-
ted with tamoxifen failure in primary breast cancer [1]. cDNA
microarray analysis of 10 tamoxifen-treated initially oestrogen
receptor-positive breast tumours requiring salvage surgery
were compared with 8 tumours from patients who were
disease-free 5 years after surgery plus tamoxifen adjuvant
therapy. In addition to ESR1, five genes (MET, FOS, SNCG,
IGFBP4 and BCL2) were validated by real-time quantitative
PCR and immunohistochemisty in the original 35 patients
and in an independent cohort from another centre (n = 33).
Whilst their paper provides a useful contribution to our
understanding of possible markers of response to hormonal
therapy, it also highlights several issues relating to the
experimental design and validation of microarray studies.
The authors recognise that this study does not identify genes
changed in response to treatment in particular individuals, as
no pre-therapy samples were included in the failure arm [1].
Measuring gene expression changes in responding and
nonresponding samples is possible within neoadjuvant and
window of opportunity studies, where pre-treatment and post-
treatment biopsies from the same patient are compared with
measures of response (pathologic complete response, change
in proliferation) [2-5]. These studies can identify consistent
changes within patient groups and can potentially identify mole-
cular profiles/pathways associated with response to therapy.
A critical step in the future validation of molecular profiles is
the extension from use in neoadjuvant/preoperative studies,
where response data are available for the vast majority of
cases, to the adjuvant setting, where most cases do not yield
hard response data. Whilst profiling of small patient cohorts
is increasingly common, authors should recognise the
objective of such studies is to identify predictive tools/
drugable targets that impact on the future of breast cancer
management. Development of predictive markers in the
adjuvant setting must reflect the difference in pathology
(preoperative studies are often biased towards larger/node-
negative tumours) and in outcome (tumour response pre-
operatively versus survival in adjuvant settings). The challenge
of validating markers must be seen as part of this process
rather than standing alone.
Vendrell and colleagues quickly progress from identifying a
47-gene signature to evaluating the predictive utility of a few
individual markers. Gene expression profiling enables a
holistic approach that is currently unrivalled by proteomic
methods, but it is clear that gene expression does not always
correlate with protein expression. The authors acknowledge
their study is an exploratory analysis, and it is certainly not the
smallest of its kind [1]. Earlier this year, microarray analysis of
tumours from three responding patients and four non-
responding patients was reported [3]. All three responding
tumours were from patients treated with exemestane only,
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while three out of four nonresponding tumours were from
patients treated with exemestane plus tamoxifen and the
remaining patient received exemestane only. A consequence
of individualised treatment is that it can be difficult to identify
appropriate numbers of patients with similar characteristics
that have been exposed to the same treatment regimen to
adequately statistically power a study. One approach to
combat small sample sizes is to perform meta-analysis and
look for common findings to refine predictive gene signatures
[6-8]. Where studies are not directly comparable, however,
they run the risk of introducing confounding factors or
missing subtle findings.
Conceptually, a multiple marker profile will be more predictive
(of prognosis or of response to therapy) than single markers.
This does not, however, guarantee that more is better. Some
markers, such as oestrogen receptor, regulate hundreds of
genes, and molecular profiles may simply duplicate what is
achieved with simple immunohistochemical analysis. The
challenge is to integrate approaches using single markers
with multiple gene signatures to find optimal predictive and
prognostic tools. The true test of clinical trials incorporating
molecular profiles is to ensure they provide added information
or confidence for decision-making over conventional
approaches [9]. Meanwhile, the search for markers goes on,
with a report in the present issue of Breast Cancer Research
suggesting that YB-1 is a stronger predictor of relapse and
disease-specific survival than oestrogen receptor or HER-2
across all tumour subtypes, as well as being predictive of
breast-cancer-specific survival in tamoxifen-treated patients
(P = 0.001) [10]. Many different but equally predictive gene
lists have been identified for predicting prognosis [11], and it
remains to be seen whether there are multiple predictive
markers of response to different therapies.
The candidate molecular signature put forward by Vendrell
and colleagues [1] must be considered in conjunction with
similar studies looking at treatment response. Each new
profile should take us closer to refining the genes and path-
ways that accurately reflect the action of a particular
treatment and ultimately the elimination of cancerous tissue,
allowing us to select the most effective agent for individuals.
We must both acknowledge that differences in experimental
design and cohort selection impact on our ability to interpret
the results of such studies and devise appropriate strategies
to integrate current knowledge within the design of future
clinical trials, validating novel approaches for choosing the
optimal treatment.
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